Physician profile
Sheng Fu
NPI 1972998961
$19,015.63
in general payments reported to CMS, 2019-2025
34 companies · $4,447 in 2025
The $4,447 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $2,331 · 2021: $832 · 2022: $5,005 · 2023: $1,682 · 2024: $2,485 · 2025: $4,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,083 · Travel and Lodging: $2,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,083.32 |
| Travel and Lodging | $2,530.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,342.40 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Coronary, Cardiomems |
| Boston Scientific Corporation | $2,537.63 | 2019-2025 | Ekosonic, Eluvia, Watchman Flx |
| Stryker Corporation | $2,360.90 | 2025 | Core |
| Medtronic, INC. | $1,638.71 | 2022-2025 | Symplicity G3, Hvad Pump Implant Kit, Ffrangio |
| Astrazeneca Pharmaceuticals Lp | $950.77 | 2019-2025 | Farxiga, Wainua |
| Actelion Pharmaceuticals US, INC. | $847.41 | 2022-2025 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $740.59 | 2019-2025 | Mitris Resilia Mitral Valve, Hemosphere |
| Cvrx, INC. | $699.50 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $672.20 | 2020-2024 | Repatha |
| Pfizer INC. | $635.83 | 2019-2025 | |
| Abiomed | $511.12 | 2022-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $432.98 | 2022-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.64 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $323.87 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.09 | 2023-2025 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.76 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $218.92 | 2022-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $186.20 | 2023-2024 | |
| Lantheus Medical Imaging, INC. | $118.93 | 2019-2022 | |
| Scpharmaceuticals INC. | $116.23 | 2023-2024 | |
| Medtronic Vascular, INC. | $108.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $102.98 | 2023-2024 | Inpefa |
| Inari Medical, INC. | $101.20 | 2021 | |
| Eurofins Viracor, LLC | $98.31 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.75 | 2022-2025 | |
| Bridgebio Pharma, INC. | $56.89 | 2025 | Attruby |
| Vital Connect, INC | $52.05 | 2023-2025 | Vitalpatch Rtm |
| Chiesi USA, INC. | $46.34 | 2024-2025 | Kengreal, Cleviprex |
| Janssen Pharmaceuticals, INC | $39.31 | 2022-2023 | Xarelto |
| Masimo Corporation | $37.89 | 2024-2025 | |
| Terumo Medical Corporation | $24.03 | 2024 | Metacross Otw |
| Astellas Pharma US INC | $21.98 | 2023 | Cresemba |
| United Therapeutics Corporation | $16.29 | 2024 | Orenitram, Remodulin |
| Cardiovascular Systems INC. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheng Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.